NeuroPace Q2 Revenue Jumps 17% to $22.8M, Loss Narrows; Cash Runway Solid
NPCE sits 99% above its 52-week low of $7.563.
Summary
NeuroPace reported Q2 2026 revenue of $22.8 million, up 17% year-over-year, with a narrower net loss and solid cash position. The core RNS System business is growing, and the company remains in compliance with debt covenants.
Key Events · Earnings and Guidance · NPCE
-
Q2 Revenue Beats, Up 17%
Revenue reached $22.8 million, driven by higher RNS System unit sales from both initial implants and replacements, compared to $19.5 million in Q2 2025.
-
Net Loss Narrows Significantly
Net loss from continuing operations improved to $6.2 million from $10.0 million a year ago, helped by revenue growth and lower interest expense after refinancing.
-
Cash Position and Covenant Compliance
Cash, equivalents, and short-term investments totaled $51.7 million. Trailing 12-month RNS System revenue of $89.2 million exceeded the $72.8 million covenant minimum, and the company was in full compliance with all MidCap credit agreement covenants.
-
DIXI Medical Exit Formalized as Discontinued Ops
The DIXI Medical distribution business is now presented as a discontinued operation, removing historical revenue and cost variability from continuing operations.
Analysis · NPCE · Industrial Applications And Services
A strong second quarter underscores the resilience of NeuroPace's core business. Revenue climbed 17% year-over-year to $22.8 million, while the net loss from continuing operations shrank to $6.2 million from $10.0 million. Gross margins held near 83%, and the quarter ended with $51.7 million in cash and investments. Importantly, trailing 12-month RNS System revenue of $89.2 million comfortably clears the $72.8 million covenant minimum under the MidCap credit agreement. The filing also formalizes the DIXI Medical distribution exit as a discontinued operation, removing a source of revenue variability. Against the backdrop of the recent FDA setback for the IGE label expansion, this quarter shows the core RNS business is performing well and the balance sheet can support ongoing operations and regulatory efforts.
At the time of this filing, NPCE was trading at $15.03 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $513.1M. The 52-week trading range was $7.56 to $19.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.